Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zafgen Inc (ZFGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,646
  • Shares Outstanding, K 37,315
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,370 K
  • 60-Month Beta -0.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.44
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +31.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.55 +1.57%
on 04/18/19
3.10 -16.45%
on 03/19/19
-0.47 (-15.36%)
since 03/18/19
3-Month
2.55 +1.57%
on 04/18/19
5.45 -52.48%
on 02/11/19
-2.15 (-45.36%)
since 01/18/19
52-Week
2.55 +1.57%
on 04/18/19
12.35 -79.04%
on 09/27/18
-4.29 (-62.35%)
since 04/18/18

Most Recent Stories

More News
Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zafgen, Inc. (Nasdaq:ZFGN) (the "Company") a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by...

ZFGN : 2.59 (-3.00%)
Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc.

Amyris, Inc. (AMRS)

QTNA : 24.28 (+0.25%)
AMRS : 5.02 (+20.10%)
WBC : 133.00 (+0.05%)
IRTC : 68.92 (+0.75%)
ORN : 2.71 (unch)
ZFGN : 2.59 (-3.00%)
OSMT : 4.08 (+1.24%)
Look for Shares of Zafgen Inc to Potentially Pullback after Yesterday's 1.46% Rise

Zafgen Inc (NASDAQ:ZFGN) traded in a range yesterday that spanned from a low of $2.72 to a high of $2.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $2.77...

ZFGN : 2.59 (-3.00%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Zafgen, Inc. investors ("Zafgen" or the "Company") (NASDAQ: ZFGN) concerning the Company and its officers' possible violations of...

ZFGN : 2.59 (-3.00%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zafgen, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Zafgen, Inc. ("Zafgen" or the "Company") (NASDAQ: ZFGN) investors concerning the Company and its officers' possible violations...

ZFGN : 2.59 (-3.00%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zafgen, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Zafgen, Inc. ("Zafgen" or the "Company") (NASDAQ: ZFGN) investors concerning the Company and its officers'...

ZFGN : 2.59 (-3.00%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Zafgen, Inc. investors ("Zafgen" or the "Company") (NASDAQ: ZFGN) concerning the Company and its officers' possible violations of...

ZFGN : 2.59 (-3.00%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors

Law Offices of Howard G. Smithannounces an investigation on behalf of Zafgen, Inc. investors ("Zafgen" or the "Company") (NASDAQ:ZFGN) concerning the Company and its officers' possible violations...

ZFGN : 2.59 (-3.00%)
Zafgen to Present at the 31st Annual ROTH Conference

Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic...

ZFGN : 2.59 (-3.00%)
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

Key highlights of the past week are regulatory and pipeline developments.

CELG : 93.76 (-0.57%)
VRTX : 168.16 (+0.71%)
ZFGN : 2.59 (-3.00%)
AMAG : 11.83 (-0.67%)
REGN : 333.34 (-2.81%)
SNY : 41.31 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ZFGN with:

Business Summary

Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity...

See More

Key Turning Points

2nd Resistance Point 2.82
1st Resistance Point 2.70
Last Price 2.59
1st Support Level 2.51
2nd Support Level 2.44

See More

52-Week High 12.35
Fibonacci 61.8% 8.61
Fibonacci 50% 7.45
Fibonacci 38.2% 6.30
Last Price 2.59
52-Week Low 2.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar